Literature DB >> 8161782

Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor.

K Hildén1, T Tuuri, M Erämaa, O Ritvos.   

Abstract

Recent studies have indicated that activin A/erythroid differentiation factor is a physiologic hematopoietic growth and differentiation factor mainly for cells of the erythroid lineage. We studied the expression of the two type II activin receptor mRNAs during the differentiation of K562 erythroleukemic cells, which are known to be induced toward the erythroid lineage in response to activin or toward the megakaryoblastic lineage by phorbol myristate acetate (PMA). The cDNA of the human activin receptor type IIB (hActR-IIB) was cloned and sequenced from two RNA sources, the K562 cells and the human fetal brain, which is, of the tissues screened by Northern blot analysis, the most abundant source of ActR-IIB RNA. The cDNA encodes a predicted 512 amino acid protein containing an extracellular ligand binding domain, a hydrophobic transmembrane domain, and an intracellular serine/threonine kinase domain. The amino acid sequence is 99.2% and 98.4% homologous in the coding region to the previously described mouse and rat ActR-IIB2s, respectively, and 69% identical to the other human activin serine/threonine kinase receptor, hActR-II. The alternative splicing events in the juxtamembrane region previously reported for the respective mouse receptor were not observed during the processing of K562 cell and human fetal brain RNA. Northern analysis showed that the 10- and 2.5-kb transcripts of hActR-IIB are more abundantly expressed than the 6.0- and 3.0-kb transcripts of hActR-II in K562 cells. No changes in the steady-state levels of hActR-II and IIB mRNAs were detected upon differentiation of K562 cells by activin A or by PMA. Similarly, the receptor mRNA levels remained constant in HL-60 cells induced to either monocyte/macrophage or granulocyte-like cells by PMA or dimethyl sulfoxide, respectively. Thus, the mRNA expression levels of both receptors apparently do not correlate with the differentiation status of these cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8161782

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.

Authors:  Barbara H Jung; Stayce E Beck; Jennifer Cabral; Eddy Chau; Betty L Cabrera; Antonio Fiorino; E Julieta Smith; Melanie Bocanegra; John M Carethers
Journal:  Gastroenterology       Date:  2006-11-16       Impact factor: 22.682

2.  Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb.

Authors:  Dianne Sako; Asya V Grinberg; June Liu; Monique V Davies; Roselyne Castonguay; Silas Maniatis; Amy J Andreucci; Eileen G Pobre; Kathleen N Tomkinson; Travis E Monnell; Jeffrey A Ucran; Erik Martinez-Hackert; R Scott Pearsall; Kathryn W Underwood; Jasbir Seehra; Ravindra Kumar
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

3.  Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line.

Authors:  S Y Ying; Z Zhang
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study).

Authors:  Linda T Roten; Matthew P Johnson; Siri Forsmo; Elizabeth Fitzpatrick; Thomas D Dyer; Shaun P Brennecke; John Blangero; Eric K Moses; Rigmor Austgulen
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

5.  Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues.

Authors:  R H van Schaik; C D Wierikx; M A Timmerman; M H Oomen; W M van Weerden; T H van der Kwast; G J van Steenbrugge; F H de Jong
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 6.  Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.

Authors:  Juha J Hulmi; Tuuli A Nissinen; Fabio Penna; Andrea Bonetto
Journal:  Cells       Date:  2021-02-28       Impact factor: 6.600

7.  Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.

Authors:  H Yamashita; P ten Dijke; D Huylebroeck; T K Sampath; M Andries; J C Smith; C H Heldin; K Miyazono
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

8.  Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs.

Authors:  R H van Schaik; C D Wierikx; L H Looijenga; J W Oosterhuis; F H de Jong
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Network of microRNAs-mRNAs interactions in pancreatic cancer.

Authors:  Elnaz Naderi; Mehdi Mostafaei; Akram Pourshams; Ashraf Mohamadkhani
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

10.  A TGF-β type II receptor that associates with developmental transition in Haemonchus contortus in vitro.

Authors:  Li He; Robin B Gasser; Tingting Li; Wenda Di; Fangfang Li; Hongrun Zhang; Caixian Zhou; Rui Fang; Min Hu
Journal:  PLoS Negl Trop Dis       Date:  2019-12-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.